Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same

ABSTRACT

The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C 1-12  alkyl group optionally substituted by a C 1-4  alkoxycarbonyl group; a C 3-9  cycloalkyl, adamantyl or optionally substituted phenyl group; 
     R 1  means hydrogen or a C 1-4  alkyl group; or 
     R and R 1  together form a --(CH 2 ) n  -- chain, wherein n is 4, 5 or 6; 
     R 2  stands for hydrogen, a C 1-4  alkyl group or halogen; 
     R 3  represents hydrogen or a C 1-4  alkyl group; and 
     m is 0 or 1. 
     The compounds of the general formula (I) possess a gastroprotective effect and are useful for the prevention and therapy of ulcers of the stomach and the small intestine.

This is a continuation of co-pending application Ser. No. 07/903,246filed on 23 Jun. 1992, U.S. Pat. No. 5,252,572 which is a continuationof Ser. No. 07/307,665 filed 6 Feb. 1989, U.S. Pat. No. 5,158,951.

FIELD OF THE INVENTION

This invention relates to novel4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives and theiracid addition salts which are useful as gastroprotective agents mainlylot the therapy and prevention of ulcer.

BACKGROUND OF THE INVENTION

It is known that 4-oxo-4H-pyrido[1,2-a]pyrimidine derivatives haveanalgesic and other effects influencing the central nervous system(British Patent No. 1,209,946, U.S. Pat. No. 4,291,036 and German PatentNo. 2,414,751). One of the most advantageous representatives of thesecompounds is1,6-dimethyl-3-ethoxycarbonyl-6,7,8,9-tetrahydro-4-oxo-4H-pyrido[1,2-a]pyrimidiniummethosulfate [Arzneimittelforschung 22, 815 (1972)] used as an analgesicdrug in clinical practice. Other derivatives have been shown to exert apreferable anti-arteriosclerotic (German Patent No. 2,705,775),antiallergic and antiasthmatic (Belgian Patent Nos. 873,192 and873,194), anti-inflammatory [German Patent Nos. 2,728,198 and 2,526,983;Arzneimittelforschung 29, 766 (1979)], cardiovascular [Sankyo KenkyushoNempo 29, 75 (1977)] and selective serotonine-2 receptor-blocking (U.S.Pat. No. 4,342,870) effects. The antiulcer action of tetrahydro- andhexahydro-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid derivativeshave also been reported [Drugs Exptl. Clin. Res. 11, 493 (1985); ibidem13, 253 (1987)]. Some unsaturated 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid derivatives showed an analgesic action which, however,could not be utilized because of the hydrolyric instability of thebicyclic moiety [Magyar Kemikusok Lapja 31, 281 (1976)].

DESCRIPTION OF THE INVENTION

The invention relates to novel4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of theformula (I), ##STR2## wherein R stands for a C₁₋₁₂ alkyl groupoptionally substituted by a C₁₋₄ alkoxycarbonyl group; a C₃₋₉cycloalkyl, adamantyl or optionally substituted phenyl group;

R¹ means hydrogen or a C₁₋₄ alkyl group; or

R and R¹ together form a --(CH₂)_(n) -- chain, wherein n is 4, 5 or 6;

R² stands for hydrogen, a C₁₋₄ alkyl group or halogen;

R³ represents hydrogen or a C₁₋₄ alkyl group; and

m is 0 or 1

as well as their pharmaceutically acceptable acid addition salts andpharmaceutical preparations containing these compounds.

As used herein: the term "C₁₋₁₂ alkyl" or "C₁₋₄ alkyl" means straight orbranched chain aliphatic saturated hydrocarbyl groups such as themethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl,tert.-butyl and neopentyl group; the term "C₃₋₉ cycloalkyl" means asaturated alicyclic hydrocarbyl group optionally bearing an alkyl groupsuch as the cyclopropyl, methylcyclopropyl, cyclobutyl,2,3-dimethylcyclobutyl or cyclohexyl group; the term "optionallysubstituted phenyl" means a phenyl group, or a phenyl group mono- orpolysubstituted by halogen, C₁₋₄ alkyl, C₂₋₅ alkoxy, hydroxyl,trifluoromethyl, cyano, C₁₋₄ alkoxycarbonyl or carboxyl group orsubstituted by a methylenedioxy group; the term "halogen" meansfluorine, chlorine, bromine or iodine atom.

The compounds of the formula (I) can form acid addition salts withpharmaceutically acceptable organic and inorganic acids (e.g.hydrochlorides, hydrobromides, hydroiodides, sulfates, nitrates,perchlorates and phosphates; as well as mesylates, maleares, succinates,acetates, tartrates, lactates, fumarates and citrates).

According to another aspect of the invention, there is provided aprocess for the preparation of the new compounds of the formula (I),wherein R, R¹, R², R³ and m are the same as defined above, and theirpharmaceutically acceptable acid addition salts, which comprises

a) reacting a 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid esterof the formula (II), ##STR3## wherein R², R³ and m are the same asdefined above and R⁴ stands for a C₁₋₄ alkyl group, with an amine of theformula (III), ##STR4## wherein R and R¹ are the same as defined above;or b) reacting a 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acidmixed anhydride of the formula (IV), ##STR5## wherein R², R³ and m arethe same as defined above and R⁵ means a C₁₋₄ alkyl or a benzyl group,with an amine of the formula (III), wherein R and R¹ are the same asdefined above,

and, if desired, converting the thus obtained compound of the generalformula (I), wherein R, R¹, R², R³ and m are the same as defined above,with a pharmaceutically acceptable acid to the corresponding saltthereof or, if desired, liberating it from its salt or, if desired,liberating it from one of its salts and converting it to another saltthereof in a known way.

The process a) according to the invention is preferably carried out inthe presence of a solvent. Organic solvents commonly employed inamidation reactions may be used. The reaction temperature may be chosenaccording to the properties of the reactants. The reaction may beaccomplished at room temperature or at the boiling point of the solvent.However, another temperature may be used. If desired, reaction may becarried out at a pressure different from the atmospheric, preferablyunder an overpressure. When a water-miscible organic solvent, e.g.alcohol is used, the reaction mixture may contain an optional amount ofwater. In a number of cases, the compound of the formula (I) obtained isprecipitated from the reaction mixture after dilution with water and maybe recovered by filtration. Alternatively it may be isolated byrecrystallization of the residue alter evaporation of the solvent.

In the process b) according to the invention, the compound of theformula (IV), wherein R², R³ and m are the same as defined above and R⁵means a C₁₋₄ alkyl or benzyl group, is prepared in situ by using astarting material the carboxylic acid of the formula (V), ##STR6##wherein R² and R³ are the same as defined above, and the chloroformateester of the formula (VI),

    Cl--COOR.sup.5                                             (VI)

wherein R⁵ is the same as defined above, in a manner known per se.

According to an embodiment of the process b), a compound of the formula(V) is dissolved in an organic solvent, preferably in a chlorinatedhydrocarbon (most preferably in chloroform) or in an ether, (mostpreferably in dioxane or tetrahydrofuran) and, after adding atrialkylamine, preferably triethylamine or tributylamine, a compound ofthe formula (VI), preferably methyl, ethyl, benzyl or isopropylchloroformate is dropwise added to the solution obtained at atemperature between -30° C. and 50° C., preferably between -20° C. and0° C. To the compound of the formula (IV) thus obtained, wherein R⁵ isthe same as defined above, an amine of the general formula (III) isadded dropwise (if desired, as a solution in the solvent defined aboveor, on the use of its acid addition salt, together with a trialkylamine,preferably with triethylamine or tributylamine), and the reactionmixture is stirred at the temperature range defined above and thenallowed to warm to room temperature and subsequently washed with anaqueous sodium hydrogen carbonate solution and then with water. Afterdrying, the reaction mixture is evaporated and the residue isrecrystallized from a suitable solvent.

The ratio of the reactants may arbitrarily be selected in both processesa) and b). It is preferable to react 1 mole of a compound of the formula(II) or (IV), wherein R², R³, R⁴ and R⁵ are the same as defined above,with 1 to 10 moles of the amine of the formula (III), wherein R and R¹are the same as defined above.

A part of the compounds containing a bridgehead nitrogen used asstarting materials are known. The starting substances of the formulae(II) and (V) are known from the literature [Arnzeimittelforschung 22,815 (1972)] or may be prepared in an analogous manner. The amines of theformula (III) and compounds of the formula (VI) are commerciallyavailable.

The toxicity of the compounds of the formulae (I) and (II) is low, ingeneral their oral LD₅₀ values are higher than 250 mg/kg in rats andmice.

The compounds of the formula (I) and their pharmaceutically acceptablesalts possess a significant gastroprotective effect and exert theirprotective and healing (therapeutic) action both in the stomach and thesmall intestine as well. The activity of the compounds of the formula(I) was demonstrated in standard tests generally accepted fordetermining the antiulcerogenic effect.

As an example, the efficacy on the gastric ulcer induced in rats by 0.5ml of a mixture containing 96% ethanol and hydrochloric acid in an1:0.02 volume ratio is illustrated in Table 1 [for the method, see:Gastroenterology 77, 433 (1979)].

                  TABLE 1                                                         ______________________________________                                        Protective action in rats of the compounds according                          to the invention against the gastric mucosa laesion                           induced by 96% ethanol containing hydrochloric acid                                              Oral dose Inhibition of the                                Compound           mg/kg     gastric ulcer %                                  ______________________________________                                        N-tert.-pentyl-6-methyl-4-                                                                       50        77                                               oxo-4H-pyrido[1,2-a]-                                                         pyrimidine-3-carboxamide                                                      N-isopropyl-6-methyl-4-oxo-                                                                      50        95                                               4H-pyrido[1,2-a]pyrimidine-                                                   3-carboxamide                                                                 N-neopentyl-6-methyl-4-oxo-4H-                                                                   100       48                                               pyrido[1,2-a]pyrimidine-3-                                                    carboxamide                                                                   6-methyl-4-oxo-3-pyrrolidino-                                                                    50        53                                               carbonyl-4H-pyrido[1,2-a]-                                                    pyrimidine                                                                    N,6-dimethyl-4-oxo-4H-pyrido-                                                                    100       48                                               [1,2-a]pyrimidine-3-carboxamide                                               N-propyl-6-methyl-4-oxo-4H-                                                                      12.5      69                                               pyrido[1,2-a]pyrimidine-3-                                                    carboxamide                                                                   ______________________________________                                    

The effect of the compounds according to the invention, given asexamples, against the indomethacin-induced ulcer [Arch. Int.Pharmacodyn. 117, 113 (1964)] is shown in Table 2.

                  TABLE 2                                                         ______________________________________                                        Inhibition of the indomethacin-induced gastric                                mucosa laesion in rats                                                                           Oral dose Inhibition of the                                Compound           mg/kg     gastric ulcer %                                  ______________________________________                                        6-methyl-4-oxo-3-pyrrolidino-                                                                    50        46                                               carbonyl-4H-pyrido[1,2-a]-                                                    pyrimidine                                                                    N,6-dimethyl-4-oxo-4H-pyrido-                                                 [1,2-a]pyrimidine-3-carboxamide                                                                  50        64                                               N-tert.-octyl-6-methyl-4-oxo-                                                                    50        15                                               4H-pyrido[1,2-a]pyrimidine-                                                   3-carboxamide                                                                 N-tert.-pentyl-6-methyl-4-oxo-                                                                   100       38                                               4H-pyrido[1,2-a]pyrimidine-                                                   3-carboxamide                                                                 N-neopentyl-6-methyl-4-oxo-                                                                      50        43                                               4H-pyrido[1,2-a]pyrimidine-                                                   3-carboxamide                                                                 N-isopropyl-6-methyl-4-oxo-                                                                      100       88                                               4H-pyrido[1,2-a]pyrimidine-                                                   3-carboxamide                                                                 N-propyl-6-methyl-4-oxo-4H-                                                                      12.5      48                                               pyrido[1,2-a]pyrimidine-                                                      3-carboxamide                                                                 ______________________________________                                    

The inhibiting effectN-propyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide on theformation of the indomethacin-induced duodenal ulcer in rats is given asan example. This compound was administered in a dose of 50 mg/kg on 4consecutive days. On the 2nd day, a 15 mg/kg oral dose of indomethacinwas given to unstarved rats. The ulcer formation was determined in thesmall intestine by using the method of Tsuromi [J. Pharm. Dyn. 3, 659(1980)] on the 3rd day following the administration of indomethacin. Incomparison to the control, the compound according to the inventionexerted an inhibition of 58% on the ulcer formation.

The compound of the formula (I) or its salts may therapeutically be usedin the form of compositions containing the active ingredient in anadmixture with inert solid or liquid organic or inorganic carriers.These compositions can be prepared by using methods well known in thepharmaceutical industry.

The compositions may be formulated for oral or parenteral use in theform of e.g. tablets, dragees, capsules or in the sustained-releasevariants thereof. The compositions may contain suitable solid diluentsor carriers, sterile aqueous solvents or non-toxic organic solvents. Thecompositions for oral use may be supplemented with sweetening orflavoring (aromatizing) agents which are suitable for this purpose.

Tablets for oral use may contain: carriers such as lactose, sodiumcitrate, or calcium carbonate; disintegrating agents such as starch oralginic acid; and sliding agents such as talc, sodium lauryl sulfate ormagnesium stearate. The carrier in capsules may be e.g. lactose orpolyethylene glycol. Aqueous suspensions may contain emulsifying orsuspending agents. The diluent of a suspension in an organic solvent maybe glycerol, ethanol, chloroform and the like.

The compositions for parenteral use are solutions or suspensions of theactive ingredient in a suitable medium such as peanut oil, sesame oil,polypropylene glycol or water.

The active ingredient content of the pharmaceutical compositionsaccording to the invention may be varied within wide limits say, 0.005to 99%.

The daily dose of the active ingredient may also be varied within widelimits and depends on the severity of the disease as well as on the ageand body weight of the patient, on the formulation of the compositionand efficiency of the active ingredient used. For oral use, the dailydose of the active ingredient is commonly between 0.05 and 15 mg/kgdaily once or in divided doses. However, the above data are onlyinformative in character, which may be increased or lowered, dependentlyon the demands of the situation and prescriptions of the physician. Whenjustified, compositions (formulations) differing from the aboveapplication forms may also be used.

SPECIFIC EXAMPLES

The invention is illustrated in detail by the following non-limitingExamples.

EXAMPLE 1 Preparation ofN,6-dimethyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A solution containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. while stirring and cooling by ice-salt. To this mixture, 6.5 ml(0.08 mol) of methyl chloroformate dissolved in 40 ml chloroform aredropped at -20° C. during 10 minutes. After stirring for 5 minutes, asolution containing 2.5 g (0.08 mol) of methylamide (prepared frommethylamine hydrochloride in chloroform by adding triethylamine) in 80ml of chloroform is added dropwise to the reaction mixture at -18° C.during 30 minutes. After stirring below -10° C. for 1 hour, the reactionmixture is allowed to stand in the refrigerator overnight. Next day thereaction mixture is washed 3 times with 140 ml of 5% sodium hydrogencarbonate solution each and then with 140 ml of water. The organic phaseis dried over anhydrous sodium sulfate and evaporated under reducedpressure. The residue is stirred with 150 ml of 10% hydrochloric acid atroom temperature for 1 hour, then the precipitated starting material,6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid weighing 10g is filtered off. The pH value of the aqueous filtrate is adjusted to 9by adding 20% sodium hydroxide solution and then extracted 3 times with100 ml of chloroform each. The combined organic phase is dried overanhydrous sodium sulfate and evaporated. After recrystallization of theresidue from ethanol, 3.2 g (45.5%) of the name lemon-yellow product areobtained, m.p.: 208°-210° C.

Analysis: Calculated for C₁₁ H₁₁ N₃ O₂ C 60.82; H 5.10; N 19.34%; foundC 60.91; H 5.18; N 19.31%.

EXAMPLE 2 Preparation ofN-propyl-6-methyl-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is added dropwise to the abovemixture at -10° C. during 20 minutes. After stirring for 5 minutes, asolution containing 5.2 g (0.088 mol) of propylamine in 80 ml ofchloroform is added dropwise at -15° C. during 30 minutes, then themixture is stirred for 1 hour below -10° C. Then the mixture is allowedto stand overnight under cooling by ice. For working up, the chloroformmixture is washed 3 times with 150 ml of 5% sodium hydrogen carbonatesolution each and then 3 times with 150 ml of water each. The chloroformphase is dried over anhydrous sodium sulfate, filtered and evaporated togive 16.8 g (85.6%) of the named product in the form of yellow crystalsafter recrystallization from ethanol, m.p.: 158°-160° C.

Analysis: Calculated for C₁₃ H₁₅ N₃ O₂ C 63.66; H 6.16; N 17.13%; foundC 63.72; H 6.24; N 17.34%.

EXAMPLE 3 Preparation ofN-isopropyl-6-methyl-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mole) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -12° C. and -16° C. during 30 minutes. Afterstirring for 5 minutes, 5.2 g (0.088 mol) of isopropylamine dissolved in80 ml of chloroform are dropped to the above solution at -15° C. during40 minutes, then the mixture is stirred for 1 hour at the sametemperature and thereafter maintained under cooling by ice.

For working up, the mixture is washed 3 times with 150 ml of 5% sodiumhydrogen carbonate solution each and then 3 times with 150 ml of watereach. After during over anhydrous sodium sulfate, the chloroformsolution is filtered and evaporated to give 13.2 g (67.3%) of the namedproduct as yellow crystals after recrystallization from ethanol, m.p.:165°-169° C.

Analysis: Calculated for C₁₃ H₁₅ N₃ O₂ C 63.66; H 6.16; N 17.13%; foundC 63.57; H 6.09; N 17.18%.

EXAMPLE 4 Preparation ofN-butyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -12° C. and -15° C. during 15 minutes. Afterstirring for 5 minutes, 6.43 g (0.088 mol) of butylamine dissolved in 80ml of chloroform are dropped to the above solution at a temperaturebetween -10° C. and -15° C. during 50 minutes. The reaction mixture isstirred for 1 hour at the same temperature and then let to stand undercooling by ice. For working up, the mixture is washed 3 times with 150ml of 5% sodium hydrogen carbonate solution each and then 3 times with150 ml of water each. The organic phase is dried over anhydrous sodiumsulfate and evaporated to give 14.9 g (71.8%) of the named product asyellow crystals, m.p.: 127°-130° C.

Analysis: Calculated for C₁₄ H₁₇ N₃ O₂ C 64.85; H 6.61; N 16.20%; foundC 64.78; H 6.54; N 16.27%.

EXAMPLE 5 Preparation ofN-tert.-butyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture at-20° C. during 20 minutes. After stirring for 5 minutes, 6.47 g (0.088mol) of tert.-butylamine dissolved in 80 ml of chloroform are dropped tothe above solution at a temperature between -18° C. and -20° C. during50 minutes. The reaction mixture is stirred for 1 hour at the sametemperature and then let to stand in the refrigerator overnight. Forworking up, the mixture is washed 3 times with 150 ml of 5% sodiumhydrogen carbonate each and then 3 times with 150 ml of water each. Theorganic phase is dried over anhydrous sodium sulfate and evaporated togive 15.5 g (74.7%) of the named product as light beige crystals alterrecrystallization from ethanol, m.p.: 164°-166° C.

Analysis: Calculated for C₁₄ H₁₇ N₃ O₂ C 64.85; H 6.61; N 16.20%; foundC 64.91; H 6.75; N 16.23%.

EXAMPLE 6 Preparation ofN-pentyl-6-methyl-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxamide

A mixture containing 8.16 g (0.04 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 6.2 ml(0.044 mol) of triethylamine in 240 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 4 ml (0.042 mol) of ethylchloroformate in 20 ml of chloroform is dropped to the above mixture at-15° C. during 20 minutes. After stirring for 5 minutes, 3.835 g (0.044mol) of n-pentylamine dissolved in 40 ml of chloroform are dropped tothe above solution at -15° C. during 20 minutes. The reaction mixture isstirred below -10° C. for 1 hour and then let to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 100 ml of 5% sodium hydrogen carbonate solution each and then 3times with 100 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated to give 6.1 g (55.8%)of the named product as orange yellow crystals after recrystallizationfrom ethanol, m.p.: 112°-116° C.

Analysis: Calculated for C₁₅ H₁₉ N₃ O₂ C 65.91; H 7.01; N 15.37%; foundC 65.87; H 7.15; N 15.45%.

EXAMPLE 7 Preparation ofN-neopentyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 8.16 g (0.04 mole) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 6.2 ml(0.044 mol) of triethylamine in 240 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 3.25 ml (0.04 mol) of methylchloroformate in 20 ml of chloroform is dropped to the above solution at-16° C. during 10 minutes. After stirring for 5 minutes, 3.83 g (0.044mol) of neopentylamine dissolved in 10 ml of chloroform are dropped tothe above solution at -10° C. during 5 minutes. After stirring at -10°C. for 1 hour, the reaction mixture is washed 3 times with 80 ml of 5%sodium hydrogen carbonate solution each and then 3 times with 80 ml ofwater each. The organic phase is dried over anhydrous sodium sulfate andthen evaporated to give 6.8 g (62.2%) of the named product as yellowcrystals after recrystallization from ethanol, m.p.: 191°-194° C.

Analysis: Calculated for C₁₅ H₁₉ N₃ O₂ C 65.91; H 7.01; N 15.37%; foundC 65.89; H 6.95; N 15.39%.

EXAMPLE 8 Preparation ofN-hexyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -11° C. and -12° C. during 20 minutes. Afterstirring for 5 minutes, 8.9 g (0.088 mol) of hexylamine dissolved in 80ml of dried chloroform are dropped to the above solution at -12° C.during 35 minutes. The reaction mixture is stirred at the sametemperature for 1 hour and then let to stand under cooling by ice. Forworking up, the reaction mixture is washed 3 times with 150 ml of 5%sodium hydrogen carbonate solution each and then 3 times with 150 ml ofwater each. The organic phase is dried over anhydrous sodium sulfate,filtered and evaporated to give 16.4 g (71.3%) of the named product asyellow crystals after recrystallization from ethanol, m.p.: 116°-118° C.

Analysis: Calculated for C₁₆ H₂₁ N₃ O₂ C 66.87; H 7.36; N 14.62%; foundC 66.77; H 7.28; N 14.68%.

EXAMPLE 9

Preparation ofN-heptyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyridimine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -12° C. and -15° C. during 20 minutes. Afterstirring for 5 minutes, 10.14 g (0.088 mol) of heptylamine dissolved in80 ml of chloroform are dropped to the above solution at a temperaturebetween -11° C. and -16° C. during 50 minutes. The reaction mixture isstirred at the same temperature for 1 hour and then allowed to standunder cooling by ice. For working up, the reaction mixture is washed 3times with 150 ml of 5% sodium hydrogen carbonate solution each and then3 times with 150 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated to give 17.0 g (70.5%)of the named product as orange yellow crystals, m.p.: 118°-120° C.

Analysis: Calculated for C₁₇ H₂₃ N₃ O₂ C 67.75; H 7.69; N 13.94%; foundC 67.87; H 7.74; N 13.89%.

EXAMPLE 10 Preparation ofN-octyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -13° C. and -16° C. during 25 minutes. Afterstirring for 5 minutes, 11.37 g (0.088 mol) of octylamine dissolved in80 ml of chloroform are dropped to the above solution at a temperaturebetween -13° C. and -16° C. during 40 minutes. The reaction mixture isstirred at the same temperature for 1 hour and then allowed to standovernight under cooling by ice. For working up, the reaction mixture iswashed 3 times with 150 ml of 5% sodium hydrogen carbonate solution eachand then 3 times with 150 ml of water each. The organic phase is driedover anhydrous sodium sulfate, filtered and evaporated to obtain 15.4 g(61.0%) of the named product as yellow crystals after recrystallizationfrom ethanol, m.p.: 108°-110° C.

Analysis: Calculated for C₁₈ H₂₅ N₃ O₂ C 68.71; H 7.99; N 13.32%; foundC 68.71; H 8.08; N 13.37%.

EXAMPLE 11

Preparation ofN-tert.-octyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml chloroform is dropped to the above mixture at atemperature between -12° C. and -18° C. during 20 minutes. Afterstirring for 5 minutes, 11.37 g (0.088 mol) of tert.-octylaminedissolved in 80 ml of chloroform are dropped to the above solution at atemperature between -18° C. and -15° C. during 40 minutes. The reactionmixture is stirred at the same temperature for 1 hour and then allowedto stand overnight under cooling by ice. For working up, the reactionmixture is washed 3 times with 150 ml of 5% sodium hydrogen carbonatesolution each, then 3 times with 150 ml of water each. The organic phaseis dried over anhydrous sodium sulfate, filtered and evaporated to yield16.1 g (63.8%) of the named product as light yellow crystals afterrecrystallization from ethanol, m.p.: 126°-129° C.

Analysis: Calculated for C₁₈ H₂₅ N₃ O₂ C 68.54; H 7.99; N 13.32%; C68.68; H 8.04; N 13.40%.

EXAMPLE 12 Preparation ofN-tert.-pentyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 8.16 g (0.04 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 6.2 ml(0.044 mol) of triethylamine in 240 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 4 ml (0.042 mol) of ethylchloroformate in 20 ml of chloroform is dropped to the above mixture ata temperature between -12° C. and -17° C. during 15 minutes. Afterstirring for 5 minutes, 3.84 g (0.044 mol) of tert.-pentylaminedissolved in 40 ml of chloroform are dropped to the above solution atthe same temperature during 15 minutes. The reaction mixture is stirredfor 1 hour at about -10° C. and then allowed to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 50 ml of 5% sodium hydrogen carbonate solution each and then 3times with 50 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated. The residue slowlybecomes crystalline to give 5.9 g (54%) of the named compound, m.p.:87°-89° C. after recrystallization from ethanol.

Analysis: Calculated for C₁₅ H₁₉ N₃ O₂ C 65.90; H 7.00; N 15.37%; foundC 65.97; H 7.11; N 15.47%.

EXAMPLE 13 Preparation ofN-cyclopropyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0,088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate dissolved in 40 ml of chloroform is dropped to the abovemixture at a temperature between -10° C. and -17° C. during 25 minutes.After stirring for 5 minutes, 5.025 g (0.088 mol) of cyclopropylamine in80 ml of chloroform are dropped to the above solution at the sametemperature during 40 minutes. The reaction mixture is stirred for 1hour below -10° C. and then allowed to stand overnight under cooling byice. For working up, the reaction mixture is washed 3 times with 150 mlof 5% sodium hydrogen carbonate solution each, then 3 times with 150 mlof water each. The organic phase is dried over anhydrous sodium sulfate,filtered and evaporated to give 14.5 g (74.5%) of the named compound aslight yellow crystals after recrystallization from ethanol, m.p.:174°-176° C.

Analysis: Calculated for C₁₃ H₁₃ N₃ O₂ C 64.18; H 5.38; N 17.27%; foundC 64.25; H 5.42; N 17.21%.

EXAMPLE 14 Preparation ofN-cyclopentyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture at-10° C. during 20 minutes. After stirring for 5 minutes, 7.49 g (0.088mol) of cyclopentylamine dissolved in 80 ml of chloroform are dropped tothe above solution at -15° C. during 30 minutes. The reaction mixture isstirred for 1 hour below -10° C., then allowed to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 150 ml of 5% sodium hydrogen carbonate solution each, then 3 timeswith 150 ml of water each. The organic phase is dried over anhydroussodium sulfate, filtered and evaporated to yield 14.3 g (65.9%) of thenamed product as yellow crystals after recrystallization from ethanol,m.p.: 158°-160° C.

Analysis: Calculated for C₁₄ H₁₇ N₃ O₂ C 66.04; H 6.31; N 15.49%; found66.34; H 6.28; N 15.54%.

EXAMPLE 15 Preparation ofN-cyclohexyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture at-10° C. during 20 minutes. After stirring for 5 minutes, 8.73 g (0.088mol) of cyclohexylamine dissolved in 80 ml of chloroform are dropped tothe above solution at -15° C. during 30 minutes. The reaction mixture isstirred for 1 hour below -10° C. and then allowed to stand overnightunder cooling by ice. For working up, the reaction mixture is washed 3times with 150 ml of 5% sodium hydrogen carbonate solution each and then3 times with 150 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated to give 16.7 g (73.2%)of the named product as yellow crystals after recrystallization fromethanol, m.p.: 174°-176° C.

Analysis: Calculated for C₁₆ H₁₉ N₃ O₂ C 67.35; H 6.71; N 14.72%; foundC 67.29; H 6.67; N 14.78%.

EXAMPLE 16 Preparation ofN-cycloheptyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a pyrimidine-3-carboxylic acid and 12.4 ml(0,088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture at-10° C. during 20 minutes. After stirring for 5 minutes, 9.96 g (0.088mol) of cycloheptylamine dissolved in 80 ml of chloroform are dropped tothe above solution at a temperature between -12° C. and -15° C. during40 minutes. The reaction mixture is stirred for 1 hour below -10° C. andthen allowed to stand overnight under cooling by ice. For working up,the reaction mixture is washed 3 times with 150 ml of 5% sodium hydrogencarbonate solution each, then 3 times with 150 ml of water each. Theorganic phase is dried over anhydrous sodium sulfate, filtered andevaporated to obtain 20.4 g (85.2%) of the named compound as yellowcrystals, m.p.: 172°-174° C.

Analysis: Calculated for C₁₇ H₂₁ N₃ O₂ C 68.20; H 7.07; N 1.03%; found C68.27; H 7.18; N 14.10%.

EXAMPLE 17 Preparation ofN-phenyl-6-methyl-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -10° C. and -13° C. during 20 minutes. Afterstirring for 5 minutes, 9.19 g (0.088 mol) of aniline dissolved in 80 mlof chloroform are dropped to the above solution at a temperature between-10° C. and -13° C. during 30 minutes. The reaction mixture is stirredbelow -10° C. for 1 hour and then allowed to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 150 ml of 5% sodium hydrogen carbonate solution each and then 3times with 150 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated to give 17.6 g (78.8%)of the named compound as yellow crystals after recrystallization fromethanol, m.p.: 186°-188° C.

Analysis: Calculated for C₁₆ H₁₃ N₃ O₂ C 68.81; H 4.69% N 15.04%; foundC 68.87; H 4.70; N 15.10%.

EXAMPLE 18 Preparation ofN-(4-fluorophenyl)-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -12° C. and -17° C. during 25 minutes. Afterstirring for 5 minutes, 9.78 g (0.088 mol) of 4-fluoroaniline dissolvedin 80 ml of chloroform are dropped to the above solution at -13° C.during 30 minutes. The reaction mixture is stirred below -10° C. for 1hour, then allowed to stand overnight under cooling by ice. For workingup, the reaction mixture is washed 3 times with 150 ml of 5% sodiumhydrogen carbonate solution each and then 3 times with 150 ml of watereach. The organic phase is dried over anhydrous sodium sulfate, filteredand evaporated to give 18.3 g (77%) of the named compound as yellowcrystals after recrystallization from n-propanol, m.p.: 202°-204° C.

Analysis: Calculated for C₁₆ H₁₂ N₃ O₂ C 64.64; H 4.07; N 14.13%; foundC 64.58; H 4.11; N 14.18%.

EXAMPLE 19 Preparation ofN-(4-chlorophenyl-6-methyl-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate in 40 ml of chloroform is dropped to the above mixture ata temperature between -10° C. and -12° C. during 20 minutes. Alterstirring for 5 minutes, 11.23 g (0.088 mol) of 4-chloroaniline dissolvedin 80 ml of chloroform are dropped to the above solution at -10° C.during 35 minutes. The reaction mixture is stirred below -10° C. for 1hour, then allowed to stand overnight under cooling by ice. For workingup, the reaction mixture is washed 3 times with 150 ml of 5% sodiumhydrogen carbonate solution each and then 3 times with 150 ml of watereach. The organic phase is dried over anhydrous sodium sulfate, filteredand evaporated to yield 18.5 g (73.7%) of the named compound as yellowcrystals alter recrystallization from ethanol, m.p.: 202°-204° C.

Analysis: Calculated for C₁₆ H₁₂ N₃ O₂ C 61.25; H 3.85; N 13.39%; foundC 61.36; H 3.90; N 13.42%.

EXAMPLE 20 Preparation ofN-propyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 7.2 g (0.0378 mol) of4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 6.2 g (0.044 mol)of triethylamine in 240 ml of chloroform is cooled below -10° C. byice-salt. A solution of 3.25 ml (0.044 mol) of methyl chloroformatedissolved in 20 ml of chloroform is dropped to the above mixture at -20°C. during 20 minutes. After stirring for 5 minutes, 2.6 g (0.04 mol) ofn-propylamine dissolved in 80 ml of chloroform are dropped at -18° C.during 60 minutes. The reaction mixture is stirred for 1 hour at thesame temperature, then allowed to stand overnight under cooling by ice.For working up, the reaction mixture is washed 3 times with 70 ml of 5%sodium hydrogen carbonate solution each, then 3 times with 70 ml ofwater each. The organic phase is dried over anhydrous sodium sulfate,filtered and evaporated to yield 7.1 g (77.5%) of the named compound aslight yellow crystals after recrystallization from ethanol, m.p.:120°-122° C.

Analysis: Calculated for C₁₂ H₁₁ N₃ O₂ C 62.87; H 4.83; N 18.33%; foundC 62.81; H 4.79; N 18.39%.

EXAMPLE 21 Preparation ofN-propyl-7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate dissolved in 40 ml of chloroform is dropped to the abovemixture at -18° C. during 20 minutes. After stirring for 5 minutes, 5.2(0.088 mol) of propylamine dissolved in 80 ml of chloroform are droppedto the above solution at -18° C. during 60 minutes. The reaction mixtureis stirred at -10° C. for 1 hour, then allowed to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 150 ml of 5% sodium hydrogen carbonate solution each, then 3 timeswith 150 ml of water each. The organic phase is dried over anhydroussodium sulfate, filtered and evaporated to obtain 17.5 g (89.2%) of thenamed compound as yellow crystals after recrystallization from ethanol,m.p.: 126°-128° C.

Analysis: Calculated for C₁₃ H₁₅ N3O₂ C 63.66; H 6.16; N 17.13%; found C63.69; H 6.21; N 17.18%.

EXAMPLE 22 Preparation ofN-propyl-8-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 16.32 g (0.08 mol) of8-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 12.4 ml(0.088 mol) of triethylamine in 480 ml of chloroform is cooled below-10° C. by ice salt. A solution of 6.5 ml (0.08 mol) of methylchloroformate dissolved in 40 ml of chloroform is dropped to the abovemixture at -18° C. during 10 minutes. After stirring for 5 minutes, 5.2g (0.088 mol) of propylamine dissolved in 80 ml of chloroform aredropped to the above solution at -18° C. during 60 minutes. The reactionmixture is stirred at -10° C. for 1 hour, then allowed to stand undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 150 ml of 5% sodium hydrogen carbonate solution each, then 3 timeswith 150 ml of water each. The organic phase is dried over anhydroussodium sulfate, filtered and evaporated to give 17.3 g (88.2%) of thenamed compound as yellow crystals after recrystallization from ethanol,m.p.: 194°-196° C.

Analysis: Calculated for C₁₃ H₁₅ N₃ O₂ C 63.58; H 6.16; N 17.11%; foundC 63.58; H 6.21; N 17.19%.

EXAMPLE 23 Preparation ofN-propyl-9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 9.2 g (0.045 mol) of9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 7.05 ml(0.05 mol) of triethylamine in 280 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 3.7 ml (0.045 mol) of methyl chloroformatedissolved in 25 ml of chloroform is dropped to the above mixture at -21°C. during 10 minutes. After stirring for 5 minutes, 2.95 g (0.05 mol) ofpropylamine dissolved in 50 ml of chloroform are dropped to the abovesolution at a temperature between -21° C. and -19° C. during 45 minutes.The reaction mixture is stirred below -10° C. for 1 hour, then allowedto stand overnight under cooling by ice. For working up, the reactionmixture is washed 3 times with 70 ml of 5% sodium hydrogen carbonatesolution each, then 3 times with 70 ml of water each. The organic phaseis dried over anhydrous sodium sulfate, filtered and evaporated to give7.8 g (70.7%) of the named compound as snow-white crystals afterrecrystallization from ethanol, m.p.: 138°-140° C.

Analysis: Calculated for C₁₃ H₁₅ N₃ O₂ C 63.66; H 6.16; N 17.13%; foundC 63.69; H 6.21; N 17.18%.

EXAMPLE 24 Preparation ofN-propyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-acetic acid amide

A mixture containing 2.18 g (0.01 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-acetic acid and 1.55 ml(0.011 mol) of triethylamine in 60 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 0.945 g (0.01 mol) of methyl chloroformatein 5 ml of chloroform is dropped to the above mixture at -12° C. during7 minutes. After stirring for 5 minutes, 0.65 g (0.011 mol) ofpropylamine dissolved in 10 ml of chloroform is dropped to the abovesolution at -15° C. during 10 minutes. The reaction mixture is stirredat -15° C. for 1 hour, then allowed to stand overnight under cooling byice. For working up, the reaction mixture is washed 3 times with 40 mlof 5% sodium hydrogen carbonate solution each, then 3 times with 40 mlof water each. The organic phase is dried over anhydrous sodium sulfate,filtered and evaporated. Alter thoroughly triturating the residue withcold ethyl acetate, 0.8 g (30.9%) of the named compound is obtained,m.p.: 96°-98° C. after recrystallization from ethyl acetate.

Analysis: Calculated for C₁₄ H₁₇ N₃ O₂ C 64.85; H 6.61; N 16.20%; foundC 64.81; H 6.72; N 16.28%.

EXAMPLE 25 Preparation ofN-(1-ethoxycarbonyl-2-methylpropyl)-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 5.717 g (0.028 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 4.34 ml(0.031 mol) of triethylamine in 120 ml of chloroform is cooled below-10° C. by ice-salt. A solution of 2.52 ml (0.026 mol) of methylchloroformate in 10 ml of chloroform is dropped to the above mixture at-10° C. during 10 minutes. After stirring for 5 minutes, 3.7 g (0.028mol) of ethyl 2-aminosobutyrate dissolved in 20 ml of chloroform aredropped to the above solution at -12° C. during 30 minutes. The reactionmixture is stirred at -10° C. for 1 hour, then allowed to standovernight under cooling by ice. For working up, the reaction mixture iswashed 3 times with 50 ml of 5% sodium hydrogen carbonate solution each,then 3 times with 50 ml of water each. The organic phase is dried overanhydrous sodium sulfate, filtered and evaporated to give 5.7 g (64.2%)of the named compound as pale yellow crystals after recrystallizationfrom ethanol, m.p.: 136° C.

Analysis: Calculated for C₁₆ H₁₉ N₃ O₄ C 60.56; H 6.03; N 13.24%; foundC 60.63; H 6.13; N 13.27%.

EXAMPLE 26 Preparation ofN-adamantyl-4-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 4.08 (0.02 mole) of4-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 3.1 ml(0.022 mol) of triethylamine in 120 ml of chlroform is cooled below -10°C. by ice-salt. A solution of 2.52 ml (0.024 mol) of methylchloroformate in 10 ml of chloroform is dropped to the above mixture at-15° C. during 10 minutes. After stirring for 5 minutes, 3.33 g (0.022mol) of 1-adamantanamine dissolved in 20 ml of chloroform are dropped tothe above solution at -15° C. during 15 minutes. The reaction mixture isstirred below -10° C. for 1 hour, then allowed to stand overnight undercooling by ice. For working up, the reaction mixture is washed 3 timeswith 70 ml of 5% sodium hydrogen carbonate solution each, then 3 timeswith 70 ml of water each. The organic phase is dried over anhydroussodium sulfate, filtered and evaporated to yield 4.4 g (65.2%) of thenamed product as pale yellow crystals after recrystallization fromethanol, m.p.: 190°-193° C.

Analysis: Calculated for C₂₀ H₂₃ N₃ O₂ C 71.19; H 4.87; N 12.45%; foundC 71.24; H 4.97; N 12.51%.

EXAMPLE 27 Preparation of6-methyl-4-oxo-3-pyrrolidinocarbonyl-4H-pyrido[1,2-a]pyrimidine

A mixture containing 20.4 g (0.1 mol) of6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 15.5 ml(0.11 mol) of triethylamine in 600 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 10 ml (0.1 mol) of methyl chloroformatedissolved in 50 ml of chloroform is dropped to the above mixture at -10°C. during 30 to 35 minutes. After stirring for 20 minutes, 9 g (0.11mol) of pyrrolidine dissolved in 100 ml of chloroform are dropped to theabove solution at a temperature between -5° C. and -8° C. during 1 hour.The reaction mixture is stirred at the same temperature for 1 hour, thenallowed to stand overnight under cooling by ice. For working up, thereaction mixture is washed 3 times with 400 ml of 5% sodium hydrogencarbonate solution each, then 3 times with 400 ml of water each. Theorganic phase is dried over anhydrous sodium sulfate, filtered andevaporated. After suspending the oily residue in petroleum ether, 8.3 g(32.3%) of the named compound are obtained, which forms yellow crystalsafter recrystallization from ethanol, m.p.: 132°-134° C.

Analysis: Calculated for C₁₄ H₁₅ N₃ O₂ C 65.36; H 5.88; N 16.33%; foundC 65.01; H 6.04; N 16.57%.

EXAMPLE 28 Preparation ofN-propyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamidemethanesulfonate

After dissolving 1.527 g (0.00623 mol) ofN-propyl-6-methyl-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide byheating, 0.61 ml (0.009 mol) of methanesulfonic acid is dropped to theclear yellow solution. On cooling, 1.84 g (86.8%) of the named salt areprecipitated as a white crystalline substance, m.p.: 183°-185° C.

Analysis: Calculated for C₁₄ H₁₈ N₃ O₅ S C 49.40; H 5.33; N 12.34%;found C 49.31; H 5.25; N 12.38%.

EXAMPLE 29 Preparation ofN-propyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamidehydrochloride

After dissolving 10 g (0.041 mol) ofN-propyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide in 150ml of ethanol by heating, 10 ml of ethanol containing 20% hydrogenchloride are dropped to the clear yellow solution (pH=1 ). Aftercooling, the precipitated crystals are filtered to give 9.3 g (81.0%) ofthe title salt, m.p.: 206°-208° C.

Analysis: Calculated for C₁₃ H₁₆ ClN₃ O₂ C 55.42; H 5.72; N 14.91%;found C 55.47; H 5.81; N 14.87%.

EXAMPLE 30

Preparation ofN-cyclopentyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamidehydrochloride

After dissolving 3 g (0.011 mol) ofN-cyclopentyl-6-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide in45 ml of ethanol by heating, 10 ml of ethanol containing 20% hydrogenchloride are added to the clear yellow solution (pH=1). After cooling,the precipitated crystals are filtered to obtain 2.5 g (75.53%) of thenamed salt, m.p.: 205°-209° C.

Analysis: Calculated for C₁₅ H₁₈ ClN₃ O₂ C 58.54; H 5.89; N 13.65%;found C 58.27; H 6.11; N 13.69%.

EXAMPLE 31

Preparation ofN-cyclopentyl-7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 1.22 g (0.006 mol) of7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 0.84 ml(0.006 mol) of triethylamine in 40 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 0.46 ml (0.006 mol) of methylchloroformate in 3 ml of chloroform is dropped to the above mixture at-18° C. during 10 minutes. After stirring for 5 minutes, 0.56 g (0.0066mol) of cyclopentylamine dissolved in 6 ml of chloroform is dropped tothe above solution which is then stirred at -10° C. for 1 hour andallowed to stand overnight under cooling by ice. For working up, thereaction mixture is washed 3 times with 15 ml of 5% sodium hydrogencarbonate solution each, then 3 times with 15 ml of water each. Theorganic phase is dried over anhydrous sodium sulfate, filtered andevaporated to give 0.8 g (49.2%) of the named compound as white crystalsafter recrystallization from ethanol, m.p.: 162°-164° C.

Analysis: Calculated for C₁₅ H₁₇ N₃ O₂ C 66.04; H 6.31; N 15.49%; foundC 66.19; H 6.57; N 15.42%.

EXAMPLE 32

Preparation ofN-cyclopentyl-8-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 1.22 g (0.006 mol) of8-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 0.84 ml(0.006 mol) of triethylamine in 40 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 0.46 ml (0.006 mol) of methylchloroformate in 3 ml of chloroform is dropped to the above mixture at-15° C. during 10 minutes. After stirring for 5 minutes, 0.56 g (0.0066mol) of cyclopentylamine dissolved in 6 ml of chloroform is dropped tothe above solution. The reaction mixture is stirred at -10° C. for 1hour, then allowed to stand overnight under cooling by ice. For workingup, the reaction mixture is washed 3 times with 15 ml of 5% sodiumhydrogen carbonate solution each, then 3 times with 15 ml of water each.The organic phase is dried over anhydrous sodium sulfate, filtered andevaporated to yield 0.9 g (55%) of the named compound as a crystallinesubstance after recrystallization from ethanol, m.p.: 220°-222° C.

Analysis: Calculated for C₁₅ H₁₇ N₃ O₂ C 66.04; H 6.31; N 15.49%. foundC 66.11; H 6.38; N 15.41%.

EXAMPLE 33

Preparation ofN-cyclopentyl-9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide

A mixture containing 1.22 g (0.006 mol) of9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid and 0.84 ml(0.006 mol) of triethylamine in 40 ml of chloroform is cooled below -10°C. by ice-salt. A solution of 0.46 ml (0.006 mol) of methylchloroformate in 3 ml of chloroform is dropped to the above mixture at-15° C. during 10 minutes. After stirring for 5 minutes, 0.56 g (0.0066mol) of cyclopentylamine dissolved in 6 ml of chloroform is dropped tothe above reaction mixture which is then stirred at -10° C. for 1 hourand then allowed to stand overnight under cooling by ice. For workingup, the reaction mixture is washed 3 times with 15 ml of 5% sodiumhydrogen carbonate solution each, then 3 times with 15 ml of water each.The organic phase is dried over anhydrous sodium sulfate, filtered andevaporated to yield 0.6 g (36.9%) of the named compound as a whitecrystalline substance after recrystallization from ethanol, m.p.:170°-171° C.

Analysis: Calculated for C₁₅ H₁₇ N₃ O₂ C 66.04; H 6.31; N 15.49%; foundC 65.94; H 6.27; N 15.53%.

We claim:
 1. A compound of the Formula (I) ##STR7## wherein R is a C₁ toC₁₂ alkyl group;R¹ is hydrogen or a C₁ to C₄ alkyl group; R² ishydrogen, a C₁ to C₄ alkyl group or halogen; and R³ is hydrogen or a C₁to C₄ alkyl group; or a pharmaceutically acceptable acid addition saltthereof.
 2. A compound of the Formula (I) ##STR8## wherein R is a C₂ toC₁₂ alkyl group excluding t-butyl;R¹ is hydrogen or a C₁ to C₄ alkylgroup; R² is hydrogen, a C₁ to C₄ alkyl group or halogen; and R³ ishydrogen or a C₁ to C₄ alkyl group; or a pharmaceutically acceptableacid addition salt thereof.
 3. A compound of the Formula (IA) ##STR9##wherein R is propyl, isopropyl, tert-pentyl, or neopentyl; andR² is C₁to C₄ alkyl; or a pharmaceutically acceptable acid addition saltthereof.
 4. The compound of the Formula (I) defined in claim 3 which isN-isopropyl-6-methyl-4-oxo-4H- pyrido(1,2-a)-pyrimidine-3-carboxamide ora pharmaceutically acceptable acid addition salt thereof.
 5. Thecompound of the Formula (I) defined in claim 3 which isN-propyl-6-methyl-4-oxo-4H-pyrido(1,2-a)- pyrimidine-3-carboxamide or apharmaceutically acceptable acid addition salt thereof.
 6. An anti-ulcerpharmaceutical composition which comprises as active ingredient atherapeutically effective amount of the compound of the Formula (I)defined in claim 1 or a pharmaceutically acceptable acid addition saltthereof in admixture with a pharmaceutically acceptable inert carrier.